samedan logo
 
 
spacer
home > news > detailed info
INDUSTRY NEWS AND PRESS RELEASES

BioIVT Acquires UK-based Clinical Trials Laboratory Services

BioIVT

Acquired donor center and laboratory enables BioIVT to ship high quality blood products and blood-derived immune cells efficiently to researchers throughout Europe

BioIVT, a leading provider of research models and services for drug development, today announced that it has acquired Clinical Trials Laboratory Services (CTLS), a donor center and laboratory based in London, UK. CTLS provides dedicated high-quality serum, plasma and blood collection services. It also offers full-service cell processing capabilities on site.

“We are delighted that CTLS is now part of BioIVT,” said BioIVT CEO Jeff Gatz. “This is BioIVT’s first donor center in Europe and we are excited to be able to address our clients’ needs by offering fresh blood and blood-derived products. CTLS expands our immune cell offering, which is one of the fastest growing segments of our company. This acquisition increases our capabilities and improves the efficiency with which we can deliver high quality biospecimens to our clients in Europe.”

All CTLS employees will join BioIVT and CTLS’ London headquarters will become the primary site in Europe for donor collections.

This acquisition increases BioIVT’s capacity to produce fresh peripheral blood mononuclear cells and other immune cell subsets such as natural killer cells, B cells, and T cells to meet clients’ research needs. It also enables BioIVT to ship fresh blood and blood-derived products to researchers anywhere in Europe within 24 hours.

“CTLS is an excellent addition to BioIVT,” said UK General Manager Kelly Sapsford. “The companies complement each other, with CTLS employees sharing our strong work ethic, commitment to supplying the highest quality biospecimens, and unremitting desire to advance medical research across Europe.”

Underscoring CTLS’ commitment to excellence, its staff members are registered with the UK-based Health & Care Professions Council.

“European researchers will be able to rely on BioIVT to provide a consistent supply of fresh blood and blood products for their studies. They will no longer need to contend with variable availability from hospital sources,” Ms. Sapsford added.

“We are excited to be joining BioIVT and expanding the breadth and depth of products and services that we can offer to our customers,” said CTLS Laboratory Director Dr. Rukhsana Ahsan. “We are looking forward to beginning this next phase of our company’s growth and development.”

Financial details about this transaction were not disclosed.

About BioIVT

BioIVT, formerly BioreclamationIVT, is a leading global provider of research models and value-added research services for drug discovery and development. We specialize in control and disease-state biospecimens including human and animal tissues, cell products, blood and other biofluids. Our unmatched portfolio of clinical specimens directly supports precision medicine research and the effort to improve patient outcomes by coupling comprehensive clinical data with donor samples. Our PHASEZERO® Research Services team works collaboratively with clients to provide target and biomarker validation, phenotypic assays to characterize novel therapeutics, clinical assay development and in vitro hepatic modeling solutions. And as the premier supplier of ADME-toxicology model systems, including hepatocytes and subcellular fractions, BioIVT enables scientists to better understand the pharmacokinetics and drug metabolism of newly-discovered compounds and their effects on disease processes. By combining our technical expertise, exceptional customer service, and unparalleled access to biological specimens, BioIVT serves the research community as a trusted partner in elevating science. For more information, please visit www.bioivt.com or follow the company on Twitter @BioIVT.
phone +1 516 483 1196
email customerservice@bioivt.com
web www.bioivt.com/
email PO Box 770, Hicksville, NY, 11802-0770
 
Print this page
Send to a friend
   
spacer
News and Press Releases

Datwyler celebrates official opening of its new production plant with First Line standard in Middletown, Del

• The new facility in Middletown, Del., is Datwyler’s third facility with First Line standard which will be catering to the markets in North and South America • Approximately 120 jobs will be created, with the majority staffed from the local community • With the Middletown facility, Datwyler will be able to increase its global First Line production by 50 percent by 2020 • First Line is specially designed to manufacture biotech and pharmaceutical elastomer components in a fully integrated good manufacturing practice (GMP) environment
More info >>


White Papers

Cleaning Validation: What do you need to consider to ensure a successful outcome?

RSSL

Cross contamination must be avoided in the Pharmaceutical industry at all costs and successful cleaning validation ensures that patients are not put at risk due to cross contamination. The process can be divided into a number of sections each of which must be fully understood and areas of concern addressed to ensure a successful outcome across the entire process. This spans both the manufacturing and subsequent analytical and microbological support. The data used to confirm a positive/successful cleaning validation is underpinned by the results of validated analytical methods. It is essential that these results are truly representative as patient safety is based upon the absence of equipment residues. So what are those areas of concern, what affects your ability to get a successful outcome and what do you need to consider when carrying out a Cleaning Validation exercise?
More info >>

Industry Events

14th Annual Biomarkers Congress

21-22 February 2019, Manchester Central Convention Complex, UK

Oxford Global is proud to present for the 14th year our flagship Biomarkers Congress, taking place 21 – 22 February 2019 in Manchester, UK. An updated programme ensures you will benefit from talks on the latest strategies and technologies impacting growth in the biomarker industry.
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement